Lastly, scRNA-seq analysis of 31 GBM samples identified the NK-marker CD161 (KLRB1) as a novel potential immunotherapeutic target; specifically, the authors identified CD161 as an overexpressed gene in cytotoxic CD8 T cells [89]. This evidence concerns the gene KLRB1 and glioblastoma.